In the tumor microenvironment (TME), Tregs (tumor-infiltrating Tregs or ti-Tregs) have been shown to contribute to the suppression of antitumor immune responses and the development of an immunosuppressive TME in distinct cancer types.3 4 This protumoral role of Tregs is corroborated by the finding that a high Foxp3+ Treg infiltration correlates with a poor prognosis in multiple cancer types.5 6 Moreover, Tregs have been shown to hamper the efficacy of immunotherapy,7 emphasizing the need for potent and specific ti-Treg targeting strategies. The gene discussed is FOXP3; the disease is neoplasm.